Menu Search
Equities

Olympus Corp

OLY:FRA

Olympus Corp

Actions
  • Price (EUR)14.50
  • Today's Change0.00 / 0.00%
  • Shares traded65.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 14:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Olympus Corp is a Japan-based company mainly engaged in the manufacture and sale of endoscopes, therapeutic equipment, scientific and other products. The Company operates through three business segments. The Endoscope segment provides gastrointestinal endoscopes, surgical endoscopes, and medical services. The Therapeutic Equipment segment provides gastrointestinal treatment instruments, urology products, respiratory products, energy devices, otolaryngology products and gynecology products. The Others segment provides biomaterials and orthopedic instruments. The Company is also engaged in the business activities, including holding companies and financial investments related to each business.

  • Revenue in USD (TTM)6.30bn
  • Net income in USD567.77m
  • Incorporated1919
  • Employees28.84k
  • Location
    Olympus Corp2951, Ishikawa-machiHACHIOJI-SHI 192-8507JapanJPN
  • Phone+81 426422111
  • Fax+81 333402062
  • Websitehttps://www.olympus.co.jp/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.